Greenwich Lifesciences Inc
NASDAQ:GLSI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Xiaomi Corp
HKEX:1810
|
CN |
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
CN |
|
R
|
Royal Century Resources Holdings Ltd
HKEX:8125
|
HK |
|
S
|
State Grid Yingda Co Ltd
SSE:600517
|
CN |
Greenwich Lifesciences Inc
Stock-Based Compensation
Greenwich Lifesciences Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Greenwich Lifesciences Inc
NASDAQ:GLSI
|
Stock-Based Compensation
$10.1m
|
CAGR 3-Years
98%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$955m
|
CAGR 3-Years
12%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
$894m
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
$494m
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$685.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Stock-Based Compensation
$993.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
Greenwich Lifesciences Inc
Glance View
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 3 full-time employees. The company went IPO on 2020-09-25. The firm is developing, GP2, a breast cancer immunotherapy focused on preventing the recurrence of breast cancer following surgery. GP2 is a nine amino acid transmembrane peptide of the human epidermal growth factor receptor two (HER2/neu) protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide specific immunity. Following GP2 immunotherapy, CD8+ cytotoxic T lymphocytes (TCL) recognizes and destroys HER2/neu-expressing cancer cells. The Company’s GP2 treatment is administered through an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. The GM-CSF is available in both liquid and lyophilized forms.
See Also
What is Greenwich Lifesciences Inc's Stock-Based Compensation?
Stock-Based Compensation
10.1m
USD
Based on the financial report for Sep 30, 2025, Greenwich Lifesciences Inc's Stock-Based Compensation amounts to 10.1m USD.
What is Greenwich Lifesciences Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
71%
Over the last year, the Stock-Based Compensation growth was 325%. The average annual Stock-Based Compensation growth rates for Greenwich Lifesciences Inc have been 98% over the past three years , 71% over the past five years .
